Piflufolastat F-18 injection drugs (Pylarify) from Sofie Co. (Notice of Intent to sole source)
ID: NOI-CC-25-000073Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/d83a8d1f1f934c2d937d82443ebb5f4e/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to negotiate a sole-source contract with Sofie Co. for the procurement of Piflufolastat F-18 injection drugs (Pylarify) essential for clinical nuclear medicine procedures at the NIH Clinical Center. This acquisition aims to secure compounded, patient-ready doses of the radiopharmaceutical, which is critical for diagnosing and treating diseases in accordance with patient care protocols. The drugs are FDA-approved and must be compounded and delivered on a time-sensitive basis due to their rapid radiation decay, making Sofie Co. the only authorized provider capable of meeting these specialized requirements. Interested parties may submit capability statements by September 18, 2024, to Lu Chang at lu-chang.lu@nih.gov, as this is not a request for proposals.

    Point(s) of Contact
    Lu Chang
    lu-chang.lu@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The objective of this procurement is to ensure the delivery of high-quality formulated drug products for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic development. This opportunity encompasses a wide range of services, including formulation development, manufacturing under current Good Manufacturing Practices (cGMP), and necessary testing to meet regulatory standards. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    SOURCES SOUGHT: Mass Spectrometry Reagents
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), is seeking qualified small business sources for the procurement of specialized Mass Spectrometry Reagents aimed at advancing research on Alzheimer’s Disease and related dementias. The objective is to establish a national resource of isogenic induced pluripotent stem cell (iPSC) lines to study genetic mutations associated with these diseases, thereby accelerating mechanistic discovery. This procurement is critical for enhancing the understanding of Alzheimer’s disease mechanisms and includes specific requirements for HPLC columns and related supplies, with the first delivery expected by July 7, 2025, and additional options extending to July 2027. Interested parties should submit their capability statements to Rashiid Cummins at Rashiid.Cummins@nih.gov by January 21, 2025, at 3:00 PM Eastern Time.
    6505--ILLUCCIX PSMA VASD
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA), through the Network Contracting Office (NCO) 22, intends to award a sole source firm-fixed price contract to Cardinal Health 414, LLC for the procurement of Illuccix PSMA radioactive therapy injections. This procurement is justified under FAR 8.405-6(a)(1)(B), as only one source can provide the unique supplies necessary for treating prostate cancer patients undergoing Positron Emission Tomography (PET) imaging. The Illuccix PSMA injection is FDA approved for patients with prostate cancer, particularly for those whose cancer may have metastasized or recurred, making it a critical component in their treatment. Interested parties must submit a tailored capability statement and relevant company information by 10:00 AM PT on January 21, 2025, to Hestia.Sim@va.gov, as the VA reserves the right to proceed with Cardinal Health if no adequate responses are received.
    Cambridge Isotope L-Glutamine
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide L-Glutamine enriched with stable isotope 13C for neuroscience research. The procurement aims to secure domestically manufactured chemicals that are essential for enhancing carbon-13 MR spectroscopy signals, which are critical for studying brain metabolism and measuring important metabolites. This initiative underscores the importance of maintaining a domestic supply of these chemicals to support ongoing research efforts at NIH and NIMH. Interested parties must submit their responses, including company information and capability statements, electronically to Joseph Kennedy at joseph.kennedy@nih.gov by January 22, 2025, as the anticipated contract duration is 12 months.
    Acquisition of SomaScan 7K and 11K Assay Kits
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure fifty-nine (59) SomaScan 7K and/or 11K Assay Kits on a sole source basis from SomaLogic Operating Co., Inc. This acquisition is intended to support the Center for Human Immunology, Inflammation, and Autoimmunity (CHI) in their systems biology research, which involves measuring a wide range of proteins in various human biological samples to enhance understanding of the immune system and related diseases. The procurement aligns with federal initiatives to advance health science research capabilities, with an estimated delivery date for the products set for December 20, 2024, and a performance period from February 21, 2025, to February 20, 2026. Interested vendors may contact Kathy Song at kathy.song@nih.gov for further information and must submit their capabilities statements within 15 days of this notice.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Assay Kits for Lumipulse instrument
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for measuring abeta42, abeta40, and pTau 217, which will support ongoing research into cognitive decline and neurodegeneration using samples from the Baltimore Longitudinal Study of Aging. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on January 15, 2025, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547. This procurement is conducted under simplified acquisition procedures and is open to all qualified offerors without set-aside restrictions.
    Nuclear Pharmaceuticals
    Dept Of Defense
    The Department of Defense, specifically the Department of the Army, is soliciting proposals for the procurement of nuclear medicine pharmaceuticals and related products for the Dwight D. Eisenhower Army Medical Center's Radiology Department. The contract aims to secure FDA-approved radiopharmaceuticals, including Technelite Generators, Cardiolite Packs, and Pylarify doses, with a focus on timely delivery and compliance with federal regulations, particularly promoting opportunities for women-owned small businesses. This procurement is critical for maintaining operational effectiveness in military healthcare, ensuring that essential medical supplies are available for patient care. Interested vendors should contact Jacquetta White at jacquetta.o.white.civ@health.mil or Sebrena L. Lane at sebrena.l.hackleylane.civ@health.mil for further details, with the contract covering multiple delivery periods from 2025 to 2028.
    Hardy Diagnostic Reagents and Supplies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.
    INTENT TO SOLE SOURCE - CAREFUSION for Pyxis rental with full support
    Health And Human Services, Department Of
    Special Notice: HEALTH AND HUMAN SERVICES, DEPARTMENT OF intends to negotiate a sole source contract with CareFusion Solutions for Pyxis rental with full support. Pyxis is a drug automated distribution system that controls the availability, access distribution, and patient safety. The contract will be in effect from the date of award to March 31, 2025. This is a non-competitive procurement based on exclusive licensing agreement. Other potential sources may submit a capability statement by July 24th, 2024.